HYBRID KOL Event on Eneboparatide: A PTHR1 Agonist for Hypoparathyroidism
June 16, 2023 | 8:30 am CT (9:30 am ET)
Location: Sheraton Grand Chicago Riverwalk Chicago, IL 

Click Here to Register & Attend

Advancing peptides for the treatment of rare endocrine and related diseases

We are a clinical stage, global company, building on our team’s established expertise to transform the lives of patients living with rare endocrine and related diseases.



Our lead clinical candidate is a potentially clinically superior therapeutic peptide in development for hypoparathyroidism.


AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development for acromegaly.

AZP-3813 Acromegal


Our management team has the collective and proven expertise necessary to advance its portfolio of innovative therapies in the clinic.

Press Releases & Recent News

Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO

Download a PDF copy of this press release: EN FR Lyon, France, and Cambridge, MA, May 7, 2024 — Amolyt ...
Read More →
Download a PDF: EN or FR

Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism

Download a PDF copy of this press release: EN FR Designation reflects the seriousness of the disease and the potential ...
Read More →
Download a PDF: EN or FR

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.

Scroll to Top